Symbols / ANEB $0.44 -12.80% Anebulo Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • PNK
ANEB Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.

Fundamentals
Scroll to Statements
Market Cap 17.78M Enterprise Value 8.76M Income -7.98M Sales — Book/sh 0.19 Cash/sh 0.22
Dividend Yield — Payout 0.00% Employees 2 IPO — P/E — Forward P/E -0.67
PEG — P/S — P/B 2.26 P/C — EV/EBITDA — EV/Sales —
Quick Ratio 6.12 Current Ratio 6.24 Debt/Eq — LT Debt/Eq — EPS (ttm) -0.18 EPS next Y -0.65
EPS Growth — Revenue Growth — Earnings 2025-11-13 ROA -45.04% ROE -69.69% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 40.78M Shs Float 3.10M Short Float 2.20%
Short Ratio 1.50 Short Interest — 52W High 3.42 52W Low 0.30 Beta -1.61 Avg Volume 66.60K
Volume 81.00 Target Price — Recom None Prev Close $0.50 Price $0.44 Change -12.80%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.44
Latest analyst target
3. DCF / Fair value
$-1.67
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.44
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-07-23 down Maxim Group Buy → Hold —
2025-05-15 main Maxim Group Buy → Buy $3
2024-11-19 reit Benchmark Speculative Buy → Speculative Buy $8
2024-10-01 reit Benchmark Speculative Buy → Speculative Buy $8
2023-10-03 reit Benchmark Speculative Buy → Speculative Buy $8
2023-09-25 reit HC Wainwright & Co. Buy → Buy $6
2023-09-21 init Maxim Group — → Buy $6
2023-09-18 init HC Wainwright & Co. — → Buy $6
2023-05-18 reit Benchmark Speculative Buy → Speculative Buy $8
2023-02-14 main Benchmark — → Speculative Buy $8
2022-07-27 init Ladenburg Thalmann — → Buy $6
2021-05-25 init Benchmark — → Buy $15
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-12-23 ENGLISH ARON R Director and Beneficial Owner of more than 10% of a Class of Security — 10,101,010 $1.25 $12,626,262
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
8.36
+0.61%
8.31
-29.49%
11.78
+72.50%
6.83
Research And Development
4.30
+21.16%
3.55
-36.63%
5.60
+89.10%
2.96
Selling General And Administration
4.92
+3.44%
4.76
-23.02%
6.18
+59.79%
3.87
General And Administrative Expense
4.92
+3.44%
4.76
-23.02%
6.18
+59.79%
3.87
Salaries And Wages
3.35
+13.03%
2.96
-17.57%
3.59
+47.29%
2.44
Other Gand A
1.58
-12.36%
1.80
-30.59%
2.59
+81.12%
1.43
Other Operating Expenses
-0.86
—
—
—
Total Expenses
8.36
+0.61%
8.31
-29.49%
11.78
+72.50%
6.83
Operating Income
-8.36
-0.61%
-8.31
+29.49%
-11.78
-72.50%
-6.83
Total Operating Income As Reported
-9.22
-11.01%
-8.31
+29.49%
-11.78
-72.50%
-6.83
EBITDA
-8.10
-0.65%
-8.05
+31.38%
-11.73
-71.75%
-6.83
Normalized EBITDA
-8.10
-0.65%
-8.05
+31.38%
-11.73
-71.75%
-6.83
EBIT
-8.10
-0.65%
-8.05
+31.38%
-11.73
-71.75%
-6.83
Total Unusual Items
—
—
—
—
Total Unusual Items Excluding Goodwill
—
—
—
—
Net Income
-8.48
-3.45%
-8.20
+30.09%
-11.73
-71.89%
-6.83
Pretax Income
-8.48
-3.45%
-8.20
+30.09%
-11.73
-71.89%
-6.83
Net Non Operating Interest Income Expense
-0.12
-226.90%
0.10
+5.83%
0.09
+1160.32%
0.01
Interest Expense Non Operating
0.38
+152.60%
0.15
0.00
0.00
Net Interest Income
-0.12
-226.90%
0.10
+5.83%
0.09
+1160.32%
0.01
Interest Expense
0.38
+152.60%
0.15
0.00
0.00
Interest Income Non Operating
0.26
+3.57%
0.25
+169.48%
0.09
+1160.32%
0.01
Interest Income
0.26
+3.57%
0.25
+169.48%
0.09
+1160.32%
0.01
Other Income Expense
-0.00
-112.90%
0.01
+122.51%
-0.04
-2215.48%
-0.00
Other Non Operating Income Expenses
-0.00
-112.90%
0.01
+122.51%
-0.04
-2215.48%
-0.00
Gain On Sale Of Security
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-8.48
-3.45%
-8.20
+30.09%
-11.73
-71.89%
-6.83
Net Income From Continuing Operation Net Minority Interest
-8.48
-3.45%
-8.20
+30.09%
-11.73
-71.89%
-6.83
Net Income From Continuing And Discontinued Operation
-8.48
-3.45%
-8.20
+30.09%
-11.73
-71.89%
-6.83
Net Income Continuous Operations
-8.48
-3.45%
-8.20
+30.09%
-11.73
-71.89%
-6.83
Normalized Income
-8.48
-3.45%
-8.20
+30.09%
-11.73
-71.89%
-6.83
Net Income Common Stockholders
-8.48
-3.45%
-8.20
+30.09%
-11.73
-71.89%
-6.83
Otherunder Preferred Stock Dividend
—
—
—
0.00
Diluted EPS
-0.25
+21.88%
-0.32
+31.91%
-0.47
-62.07%
-0.29
Basic EPS
-0.25
+21.88%
-0.32
+31.91%
-0.47
-62.07%
-0.29
Basic Average Shares
33.82
+30.97%
25.82
+2.98%
25.07
+7.41%
23.34
Diluted Average Shares
33.82
+30.97%
25.82
+2.98%
25.07
+7.41%
23.34
Diluted NI Availto Com Stockholders
-8.48
-3.45%
-8.20
+30.09%
-11.73
-71.89%
-6.83
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Assets
12.15
+198.19%
4.07
-65.10%
11.67
-25.09%
15.58
Current Assets
11.96
+241.01%
3.51
-69.94%
11.67
-25.09%
15.58
Cash Cash Equivalents And Short Term Investments
11.63
+275.80%
3.09
-72.49%
11.25
-22.69%
14.55
Cash And Cash Equivalents
11.63
+275.80%
3.09
-72.49%
11.25
-22.69%
14.55
Cash Financial
—
—
11.25
-22.69%
14.55
Receivables
0.07
0.00
—
—
Other Receivables
0.07
—
—
—
Prepaid Assets
0.26
-36.82%
0.41
-2.12%
0.42
-58.99%
1.03
Total Non Current Assets
0.18
-67.60%
0.57
0.00
0.00
Other Non Current Assets
0.18
-67.60%
0.57
—
—
Total Liabilities Net Minority Interest
0.49
+87.15%
0.26
-75.62%
1.07
+108.53%
0.51
Current Liabilities
0.49
+87.15%
0.26
-75.62%
1.07
+108.53%
0.51
Payables And Accrued Expenses
0.49
+87.15%
0.26
-75.62%
1.07
+108.53%
0.51
Payables
0.22
+43.31%
0.16
-70.74%
0.53
+40.36%
0.38
Accounts Payable
0.22
+43.31%
0.16
-70.74%
0.53
+40.36%
0.38
Current Accrued Expenses
0.26
+153.00%
0.10
-80.50%
0.53
+305.65%
0.13
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
0.00
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
11.66
+205.78%
3.81
-64.04%
10.60
-29.64%
15.07
Common Stock Equity
11.66
+205.78%
3.81
-64.04%
10.60
-29.64%
15.07
Capital Stock
0.04
+58.43%
0.03
+1.17%
0.03
+9.81%
0.02
Common Stock
0.04
+58.43%
0.03
+1.17%
0.03
+9.81%
0.02
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
41.08
+58.43%
25.93
+1.17%
25.63
+9.80%
23.34
Ordinary Shares Number
41.08
+58.43%
25.93
+1.17%
25.63
+9.80%
23.34
Additional Paid In Capital
85.51
+23.58%
69.19
+2.08%
67.78
+12.00%
60.51
Retained Earnings
-73.89
-12.97%
-65.40
-14.34%
-57.20
-25.80%
-45.47
Total Equity Gross Minority Interest
11.66
+205.78%
3.81
-64.04%
10.60
-29.64%
15.07
Total Capitalization
11.66
+205.78%
3.81
-64.04%
10.60
-29.64%
15.07
Working Capital
11.47
+253.35%
3.25
-69.37%
10.60
-29.64%
15.07
Invested Capital
11.66
+205.78%
3.81
-64.04%
10.60
-29.64%
15.07
Net Tangible Assets
11.66
+205.78%
3.81
-64.04%
10.60
-29.64%
15.07
Tangible Book Value
11.66
+205.78%
3.81
-64.04%
10.60
-29.64%
15.07
Current Notes Payable
—
—
—
—
Duefrom Related Parties Current
—
—
—
—
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Cash Flow
-6.35
+21.52%
-8.09
+16.44%
-9.68
-78.09%
-5.44
Cash Flow From Continuing Operating Activities
-6.35
+21.52%
-8.09
+16.44%
-9.68
-78.09%
-5.44
Net Income From Continuing Operations
-8.48
-3.45%
-8.20
+30.09%
-11.73
-71.89%
-6.83
Other Non Cash Items
0.38
+152.60%
0.15
—
—
Stock Based Compensation
1.45
+90.65%
0.76
-14.22%
0.88
+84.06%
0.48
Operating Gains Losses
—
—
—
—
Gain Loss On Investment Securities
—
—
—
—
Change In Working Capital
0.31
+138.32%
-0.80
-168.64%
1.16
+28.28%
0.91
Change In Receivables
-0.07
0.00
—
0.00
Change In Prepaid Assets
0.15
+1600.73%
0.01
-98.53%
0.61
-4.50%
0.64
Change In Payables And Accrued Expense
0.23
+128.10%
-0.81
-245.29%
0.56
+105.34%
0.27
Change In Accrued Expense
0.16
+137.05%
-0.43
-206.84%
0.40
+341046.61%
0.00
Change In Payable
0.07
+117.92%
-0.38
-345.98%
0.15
-43.23%
0.27
Change In Account Payable
0.07
+117.92%
-0.38
-345.98%
0.15
-43.23%
0.27
Financing Cash Flow
14.88
+23969.10%
-0.06
-100.98%
6.38
0.00
Cash Flow From Continuing Financing Activities
14.88
+23969.10%
-0.06
-100.98%
6.38
0.00
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
15.00
0.00
-100.00%
6.65
0.00
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
—
0.00
-100.00%
0.05
0.00
Net Other Financing Charges
-0.12
-87.10%
-0.06
+80.34%
-0.32
—
Changes In Cash
8.53
+204.67%
-8.15
-146.99%
-3.30
+39.29%
-5.44
Beginning Cash Position
3.09
-72.49%
11.25
-22.69%
14.55
-27.21%
19.99
End Cash Position
11.63
+275.80%
3.09
-72.49%
11.25
-22.69%
14.55
Free Cash Flow
-6.35
+21.52%
-8.09
+16.44%
-9.68
-78.09%
-5.44
Interest Paid Supplemental Data
—
—
—
0.00
Common Stock Issuance
15.00
0.00
-100.00%
6.65
0.00
Issuance Of Capital Stock
15.00
0.00
-100.00%
6.65
0.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
Preferred Stock Payments
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category